These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8420041)

  • 1. Altered specificity of alloreactive cardiac graft-infiltrating cells by prophylactic treatment with OKT3 or horse antilymphocyte globulin.
    Ouwehand AJ; Baan CC; Groeneveld K; Balk AH; Jutte NH; Bos E; Claas FH; Weimar W
    Transplantation; 1993 Jan; 55(1):154-8. PubMed ID: 8420041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-DR incompatibility predicts heart transplant rejection independent of immunosuppressive prophylaxis.
    Costanzo-Nordin MR; Fisher SG; O'Sullivan EJ; Johnson M; Heroux A; Kao W; Mullen GM; Radvany R; Robinson J
    J Heart Lung Transplant; 1993; 12(5):779-89. PubMed ID: 8241215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
    Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J
    Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol.
    Ladowski JS; Dillon T; Schatzlein MH; Peterson AC; Deschner WP; Beatty L; Sullivan M; Scheeringa RH; Clark WR
    J Cardiovasc Surg (Torino); 1993 Apr; 34(2):135-40. PubMed ID: 8320247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insensitivity to cyclosporine may explain the HLA-DRw6 recipient effect.
    Kudlacek S; Zlabinger GJ; Pohanka E; Hamilton G; Rosenmayr A; Kovarik J
    Transpl Int; 1992; 5 Suppl 1():S556-8. PubMed ID: 14621875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
    Herzberg GZ; Rossi AF; Courtney M; Gelb BD
    J Heart Lung Transplant; 1998 Dec; 17(12):1195-200. PubMed ID: 9883760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation--increased morbidity with OKT3.
    Macdonald PS; Mundy J; Keogh AM; Chang VP; Spratt PM
    Transplantation; 1993 Jan; 55(1):110-6. PubMed ID: 8380508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of graft-infiltrating lymphocytes after human heart transplantation. HLA mismatches and the cellular immune response within the transplanted heart.
    Ouwehand AJ; Baan CC; Vaessen LM; Jutte NH; Balk AH; Bos E; Claas FH; Weimar W
    Hum Immunol; 1994 Apr; 39(4):233-42. PubMed ID: 7915262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
    Hariharan S; Alexander JW; Schroeder TJ; First MR
    Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation. A plea for multicenter immunosuppressive trials.
    Ross DJ; Jordan SC; Nathan SD; Kass RM; Koerner SK
    Chest; 1996 Apr; 109(4):870-3. PubMed ID: 8635362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of HLA-DR matching on rejection after cardiac transplantation.
    Cochrane A; Benson E; Williams T; Bergin P; Esmore D
    Transplant Proc; 1992 Feb; 24(1):169-70. PubMed ID: 1539227
    [No Abstract]   [Full Text] [Related]  

  • 12. Antilymphocyte globulin with a small dose of cyclosporine A and prednisone as the induction of immunosuppression in renal allograft recipients.
    Boratyńska M; Szepietowski T; Szewczyk Z; Szydłowski Z
    Arch Immunol Ther Exp (Warsz); 1992; 40(2):163-8. PubMed ID: 1299176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antilymphocyte serum, cyclosporine and corticoids, versus OKT3, cyclosporine, and corticoids in kidney transplantation].
    Grino JM; Castelao AM; Seron D; Gonzalez C; Gil-Vernet S; Andres E; Bover J; Mestre M; Alsina J
    Presse Med; 1991 Nov; 20(40):2039-42. PubMed ID: 1837121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyclonal versus monoclonal rejection prophylaxis after heart transplantation: a randomised study.
    Balk AH; Meeter K; Simoons ML; Brouwer RM; Zondervan PE; Mochtar B; Bos E; Weimar W
    Transpl Int; 1992; 5 Suppl 1():S476-9. PubMed ID: 14621851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic therapy with OKT3 does not affect donor specific reactivity of peripheral blood lymphocytes from heart transplant recipients.
    Jutte NH; Heyse P; Daane CR; Vaessen LM; Claas FH; Balk AH; Mochtar B; Weimar W
    Transpl Immunol; 1994; 2(1):22-6. PubMed ID: 8081786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some aspects of changed histopathologic appearance of acute rejection in cardiac allografts after prophylactic application of OKT3.
    Kemnitz J; Cremer J; Schaefers HJ; Restrepo-Specht I; Haverich A; Uysal A; Heublein B; Wirth S
    J Heart Lung Transplant; 1991; 10(3):366-72. PubMed ID: 1906746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective randomized controlled trial of initial immunosuppression with ALG versus OKT3 in recipients of cardiac allografts.
    Menkis AH; Powell AM; Novick RJ; McKenzie FN; Kostuk WJ; Pflugfelder PW; Brown JE; Rochon J; Chow LH; Stiller C
    J Heart Lung Transplant; 1992; 11(3 Pt 1):569-76. PubMed ID: 1610866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posttransplant lymphoproliferative disorders in liver recipients treated with OKT3 or ALG induction immunosuppression.
    McAlister V; Grant D; Roy A; Yilmaz Z; Ghent C; Wall W
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1400-1. PubMed ID: 8442154
    [No Abstract]   [Full Text] [Related]  

  • 19. Prophylactic cytolytic therapy in heart transplantation: monoclonal versus polyclonal antibody therapy.
    Laske A; Gallino A; Schneider J; Bauer EP; Carrel T; Pasic M; von Segesser LK; Turina MI
    J Heart Lung Transplant; 1992; 11(3 Pt 1):557-63. PubMed ID: 1610864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
    Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T
    Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.